Why the study?
Does the increased prescription of spironolactone following the publication of RALES affect rates of hyperkalemia-associated morbidity and mortality?
Does the increased prescription of spironolactone following the publication of RALES affect rates of hyperkalemia-associated morbidity and mortality?
The publication of the RALES trial led to increased spironolactone prescriptions, which was associated with a real-world rise in hyperkalemia-related morbidity and mortality, highlighting the need for closer laboratory monitoring.
Closer spironolactone monitoring is warranted post-RALES; extends trial evidence by showing increased real-world hyperkalemia morbidity.
The publication of RALES was associated with abrupt increases in the rate of prescriptions for spironolactone and in hyperkalemia-associated morbidity and mortality. Closer laboratory monitoring and more judicious use of spironolactone may reduce the occurrence of this complication.
No takes yet. Share an insight, caveat, or question.
Juurlink et al. (2004) studied this question.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: